REG - CVS Group plc - Appointment of Nominated Advisor and Joint Brokers

CVSAnnouncement

13/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220713:nRSM2382Sa&default-theme=true

RNS Number : 2382S  CVS Group plc  13 July 2022

13 July 2022

CVS Group Plc

("CVS", the "Company" or the "Group")

Appointment of Nominated Advisor and Joint Brokers

 

CVS, the AIM-quoted veterinary group and one of the UK's leading providers of
integrated veterinary services, announces that it has appointed Peel Hunt LLP
as its nominated advisor and both Peel Hunt LLP and Berenberg as its joint
brokers with immediate effect.

 

CVS would like to thank their outgoing nominated advisor, Singer Capital
Markets, for their support and advice over the past ten years.

 

The Company also announces the information relating to directors' disclosures
pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies as set
out in the Appendix below.

 

Contacts:

 

 CVS Group plc                                                         via MHP Communications
 Richard Fairman, CEO
 Jenny Farrer, Company Secretary
 Peel Hunt LLP (Nominated Advisor & Broker)                            +44 (0)20 7418 8900
 Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
 Berenberg (Joint Broker)                                              +44 (0)20 3207 7800

 Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

 MHP Communications (Financial PR)                                     +44 (0)20 3128 8193

 Andrew Jaques / Simon Hockridge / Rachel Farrington / Charles Hirst

 

 

About CVS Group plc (www.cvsukltd.co.uk (http://www.cvsukltd.co.uk/) )

CVS Group is an AIM-quoted fully-integrated provider of veterinary services in
the UK, with practices in the Netherlands and the Republic of Ireland. CVS is
focused on providing high quality clinical services to its customers and their
animals, with outstanding and dedicated clinical teams and support colleagues
at the core of its strategy.

The Group has c.500 veterinary practices across its three markets, including
eight specialist referral hospitals and 35 dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties), Crematoria
(providing pet cremation and clinical waste disposal for CVS and third-party
practices), Buying Groups and the Group's online retail business ("Animed
Direct").

 The Group employs c.7,900 personnel, including c.2,100 veterinary surgeons
and c.2,900 nurses.

 

 

Appendix

 

The Company announces the following information relating to directors'
disclosures pursuant to Schedule Two, paragraph (g) of the AIM Rules for
Companies.

At the time of appointment of Richard Connell to the Board of the Company on
18 September 2007, the below disclosures were omitted: Richard Connell,
Non-Executive Chairman, held the following directorships within five years of
his appointment:

-      Keston Boilers Limited

-      Keston Holdings Limited

-      Keston Boilers Sales Limited

-      Cory Environmental Holdings Limited

-      Unifeeder A/S

-      Unifeeder Netherlands branch of Unifeeder A/S

At the time of appointment of Deborah Kemp to the Board of the Company on 2
January 2018, the following disclosure was omitted: Deborah Kemp,
Non-Executive Director, held the following directorships within five years of
her appointment to the Board of the Company; Doves Limited and William
H.Painter Limited.

At the time of appointment of David Wilton to the Board of the Company on 23
September 2021, the following disclosure was omitted: David Wilton,
Non-Executive Director, held the following directorship within five years of
his appointment to the Board of the Company; Pacman Acquisition Sub, Inc.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPSFMFMEEESEEW